卡马西平、奥卡西平酒精戒断综合征的作用。
文章的细节
-
引用
复制到剪贴板 -
巴伦R,罗伯茨N
卡马西平、奥卡西平酒精戒断综合征的作用。
中国制药。2010年4月,35 (2):153 - 67。doi: 10.1111 / j.1365-2710.2009.01098.x。
- PubMed ID
-
20456734 (在PubMed]
- 文摘
-
目的:本文的目的是评估卡马西平、奥卡西平治疗的有效性和安全性的酒精戒断综合征(AWS)并确定两特工的治疗作用。方法:相关文献是通过搜索发现的MEDLINE(1966 - 2008年6月),PubMed(1966 - 2必威国际app008年6月);科克伦数据库进行识别英文出版物。必威国际app搜索条件包括卡马西平、奥卡西平、AWS、酗酒、物质综合症撤军。结果:在七个研究中,包括612个病人,卡马西平证明显著减少酒精戒断的分数。然而,在比较与苯二氮剂试验,卡马西平的能力阻止酒精戒断癫痫(OR = 0.93;95%可信区间-14.97 = 0.06,P = NS)和震颤性谵妄(DTs);或= 1.25;95%可信区间-5.64 = 0.28,P = NS)被确定为病人人数不足的结果。在三个试验,卡马西平未能减少酒精戒断症状可能是由于延迟管理、剂量不足或样本量不足。 At daily doses of 800 mg either fixed or tapered over 5-9 days, carbamazepine was well tolerated, and safely administered when blood alcohol concentration dropped below 0.15%. The role of oxcarbazepine in AWS is undefined because of inconsistent findings in two trials. CONCLUSION: Carbamazepine has demonstrated safety, tolerability and efficacy in treatment of moderate to severe symptoms of alcohol withdrawal in the inpatient setting. However, trials of carbamazepine provide inconclusive evidence for prevention of alcohol withdrawal seizures and DTs in comparison with benzodiazepines. Benzodiazepines remain the primary treatment of moderate to severe AWS.
DrugBank数据引用了这篇文章
- 药物